

DAFTAR PUSTAKA

- Abdel-razeq, H. *et al.* (2020) 'The Application of Gail Model to Predict the Risk of Developing Breast Cancer among Jordanian Women', *Journal of Oncology*, 2020.
- American Cancer Society (2020) *Breast Cancer Risk and Prevention Breast Cancer Risk Factors You Cannot Change*, American Cancer Society. Amerika: The American Cancer Society.
- Asano, Y. *et al.* (2016) 'Platelet-lymphocyte ratio as a useful predictor of the therapeutic effect of neoadjuvant chemotherapy in breast cancer', *PloS one*, 11(7), p. e0153459.
- Avryna, P., Wahid, I. and Fauzar, F. (2019) 'Invasive Carcinoma Mammæ dengan Metastasis Orbita, Tulang, dan Paru', *Jurnal Kesehatan Andalas*, 8(1S), pp. 89–93.
- Brentnall, A.R. *et al.* (2019) 'A Case-Control Study to Add Volumetric or Clinical Mammographic Density into the Tyrer-Cuzick Breast Cancer Risk Model', *Journal of Breast Imaging*, 1(2), pp. 99–106. Available at: <https://doi.org/10.1093/jbi/wbz006>.
- Brignone, C. *et al.* (2010) 'First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity', *Journal of translational medicine*, 8(1), pp. 1–11.
- Caldarella, A. *et al.* (2013) 'Invasive breast cancer: a significant correlation between histological types and molecular subgroups', *Journal of cancer research and clinical oncology*, 139, pp. 617–623.
- Cho, U. *et al.* (2018) 'Prognostic value of systemic inflammatory markers and development of a nomogram in breast cancer', *PloS one*, 13(7), p. e0200936.
- Clendenen, T. V *et al.* (2019) 'Breast cancer risk prediction in women aged 35 – 50 years : impact of including sex hormone concentrations in the Gail model', *Breast Cancer Research*, 21(42), pp. 1–12.

- Furuholm, J. *et al.* (2021) 'Health status in patients hospitalised for severe odontogenic infections', *Acta Odontologica Scandinavica*, 79(6), pp. 436–442. Available at: <https://doi.org/10.1080/00016357.2021.1876916>.
- Gail, M.H. and Greene, M.H. (2000) 'Gail model and breast cancer', *The Lancet*, 355(9208), p. 1017.
- Giuliano, A.E., Edge, S.B. and Hortobagyi, G.N. (2018) 'the AJCC cancer staging manual: breast cancer', *Annals of surgical oncology*, 25, pp. 1783–1785.
- Goldhirsch, A. *et al.* (2007) 'Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007', *Annals of oncology*, 18(7), pp. 1133–1144.
- Graziano, V. *et al.* (2019) 'Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients', *The Breast*, 44, pp. 33–38.
- Greten, F.R. and Grivennikov, S.I. (2019) 'Inflammation and Cancer: Triggers, Mechanisms, and Consequences', *Immunity*, 51(1), pp. 27–41. Available at: <https://doi.org/https://doi.org/10.1016/j.immuni.2019.06.025>.
- Hagiwara, H. and Sunada, Y. (2004) 'Mechanism of taxane neurotoxicity', *Breast Cancer*, 11(1), pp. 82–85. Available at: <https://doi.org/10.1007/BF02968008>.
- Harbeck, N. and Gnant, M. (2017) 'Interpretation of the evidence for the efficacy and safety of statin therapy', *Lancet*, 389(10074), pp. 1134–1150.
- Hero, S.K. (2020) 'Faktor Risiko Kanker Payudara', *Jurnal Bagus*, 02(01), pp. 402–406.
- Hird, A. *et al.* (2009) 'Determining the incidence of pain flare following palliative radiotherapy for symptomatic bone metastases: results from three canadian cancer centers', *International Journal of Radiation Oncology* Biology* Physics*, 75(1), pp. 193–197.
- Huang, Z. *et al.* (2020) 'Prognostic value of neutrophil-to-lymphocyte ratio in sepsis: A meta-analysis', *The American journal of emergency medicine*, 38(3), pp. 641–647.

- Kuroi, K. *et al.* (2003) 'Weekly schedule of docetaxel in breast cancer: evaluation of response and toxicity', *Breast Cancer*, 10, pp. 10–14.
- LBBC (2015) *TAC: Taxotere, Adriamycin and Cyclophosphamide*. Available at: <https://www.lbbc.org/about-breast-cancer/treatments/chemotherapy/common-regimens/tac-taxotere-adriamycin>.
- Lin, B. *et al.* (2020) 'Tumor-infiltrating lymphocytes: Warriors fight against tumors powerfully', *Biomedicine & Pharmacotherapy*, 132, p. 110873. Available at: <https://doi.org/https://doi.org/10.1016/j.biopha.2020.110873>.
- Liu, Y. *et al.* (2021) 'Tumor Size Still Impacts Prognosis in Breast Cancer With Extensive Nodal Involvement', *Frontiers in Oncology*, 11(April), pp. 1–7. Available at: <https://doi.org/10.3389/fonc.2021.585613>.
- Loo, C.E. *et al.* (2011) 'Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype', *Journal of Clinical Oncology*, 29(6), pp. 660–666.
- Lusho, S. and Durando, X. (2021) 'Platelet-to-Lymphocyte Ratio Is Associated With Favorable Response to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer : A Study on 120 Patients', *Frontiers in Oncology*, 11(July), pp. 1–14. Available at: <https://doi.org/10.3389/fonc.2021.678315>.
- Markman, M. (2003) 'Managing taxane toxicities', *Supportive care in cancer*, 11, pp. 144–147.
- McCarthy, A.M. *et al.* (2020) 'Performance of Breast Cancer Risk-Assessment Models in a Large Mammography Cohort', *Journal of the National Cancer Institute*, 112(5), pp. 489–497. Available at: <https://doi.org/10.1093/jnci/djz177>.
- Meng, X. *et al.* (2022) 'Correlation analysis of lymphocyte-monocyte ratio with pathological complete response and clinical prognosis of neoadjuvant chemotherapy in patients with breast cancer', *Translational Oncology*, 18, p. 101355. Available at: <https://doi.org/10.1016/j.tranon.2022.101355>.
- Mijwel, S. *et al.* (2020) 'Effects of Exercise on Chemotherapy Completion and Hospitalization Rates: The OptiTrain Breast Cancer Trial', *The Oncologist*,

to organisms. Cengage Learning.

- Sinaga, C.F. and Ardayani, T. (2016) 'Hubungan pengetahuan dan sikap remaja putri tentang deteksi dini kanker payudara melalui periksa payudara sendiri di SMA Pasundan 8 Bandung Tahun 2016', *Kartika: Jurnal Ilmiah Farmasi*, 4(1), pp. 16–19.
- Singh, R. *et al.* (2020) 'Non-Hodgkin's lymphoma: a review', *Journal of family medicine and primary care*, 9(4), p. 1834.
- Starlinger, P. *et al.* (2011) 'Myelosuppression of thrombocytes and monocytes is associated with a lack of synergy between chemotherapy and Anti-VEGF treatment', *Neoplasia*, 13(5), pp. 419–427. Available at: <https://doi.org/10.1593/neo.101508>.
- Tang, S. *et al.* (2020) 'Clinical and pathological response to neoadjuvant chemotherapy with different chemotherapy regimens predicts the outcome of locally advanced breast cancer', *Gland Surgery*, 9(5), pp. 1415–1427. Available at: <https://doi.org/10.21037/gs-20-209>.
- Tong, A.W. *et al.* (2000) 'Cellular immune profile of patients with advanced cancer before and after taxane treatment', *American journal of clinical oncology*, 23(5), pp. 463–472.
- Trimonika, U., Yusmawan, W. and Marliyawati, D. (2018) 'Perbandingan Respon Klinis Penderita Karsinoma Nasofaring Yang Mendapat Kemoterapi Cisplatin Neoadjuvant Dengan Concurrent', *Diponegoro Medical Journal (Jurnal Kedokteran Diponegoro)*, 7(2), pp. 574–585.
- Tung, N.M. and Winer, E.P. (2015) 'Tumor-infiltrating lymphocytes and response to platinum in triple-negative breast cancer', *Journal of Clinical Oncology*. American Society of Clinical Oncology, pp. 969–971.
- Wang, Y., Probin, V. and Zhou, D. (2006) 'Cancer therapy-induced residual bone marrow injury: mechanisms of induction and implication for therapy', *Current cancer therapy reviews*, 2(3), pp. 271–279.
- Wibisono, A., Christian, N.W.S. and Adiputra, P.A.T. (2020) 'Hubungan antara Platelet Lymphocyte Ratio (PLR) dan respon Neoadjuvant Chemotherapy (NAC) CAF pada pasien Locally Advanced Breast Cancer', *Directory of*